Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
about
Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage.Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies.Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system
P2860
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@ast
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@en
type
label
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@ast
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@en
prefLabel
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@ast
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@en
P2093
P2860
P356
P1476
Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis
@en
P2093
Brian Custer
Elzbieta Lachert
Magdalena Letowska
Maria Agapova
P2860
P304
P356
10.1159/000371664
P577
2015-04-16T00:00:00Z